Literature DB >> 8078341

Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease.

O I Miller1, D S Celermajer, J E Deanfield, D J Macrae.   

Abstract

Inhaled low-dose nitric oxide (2, 10, 20 ppm), together with high inspired oxygen concentration (0.80), was administered after corrective operations 13 times to 10 infants (median age 6 months) who were at risk of postoperative pulmonary hypertension because of their congenital heart disease and left-to-right shunt. Inhaled nitric oxide, even in a very low dose (2 ppm), caused selective pulmonary vasodilatation. The pulmonary/systemic artery pressure ratio was a predictor of the response to nitric oxide, with a greater response being seen in those with a high ratio (> or = 0.50). In children with a high pulmonary/systemic pressure ratio, the mean pulmonary vascular resistance index fell by 37% to 42%, accompanied by only a 10% fall in the systemic vascular resistance index but a 14% to 16% rise in mean cardiac index. No toxicity was seen in any subject. This exciting new therapy may prove to be an important adjunct in the management of postoperative pulmonary hypertension in the child with congenital heart disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8078341

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  17 in total

1.  Ventricular Septal Defect.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-12

Review 2.  Review of inhaled nitric oxide in the pediatric cardiac surgery setting.

Authors:  Paul A Checchia; Ronald A Bronicki; Brahm Goldstein
Journal:  Pediatr Cardiol       Date:  2012-04       Impact factor: 1.655

Review 3.  Inhaled nitric oxide in neonates.

Authors:  N Finer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-09       Impact factor: 5.747

4.  Our paper 20 years later: Inhaled nitric oxide for the acute respiratory distress syndrome--discovery, current understanding, and focussed targets of future applications.

Authors:  R Rossaint; K Lewandowski; W M Zapol
Journal:  Intensive Care Med       Date:  2014-09-09       Impact factor: 17.440

Review 5.  Inhaled nitric oxide and related therapies.

Authors:  Frederick E Barr; Duncan Macrae
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

6.  Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response.

Authors:  B C Cannon; T F Feltes; J Kennard Fraley; R G Grifka; E M Riddle; J P Kovalchin
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

7.  Perioperative management of pulmonary hypertension in children with critical heart disease.

Authors:  Ronald A Bronicki
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-10

8.  Transfer of critically ill patients with inhaled nitric oxide.

Authors:  A P Goldman; R C Tasker; P Cook; D J Macrae
Journal:  Arch Dis Child       Date:  1995-11       Impact factor: 3.791

Review 9.  Inhaled nitric oxide therapy in neonates and children: reaching a European consensus.

Authors:  Duncan J Macrae; David Field; Jean-Christophe Mercier; Jens Møller; Tom Stiris; Paolo Biban; Paul Cornick; Allan Goldman; Sylvia Göthberg; Lars E Gustafsson; Jürg Hammer; Per-Arne Lönnqvist; Manuel Sanchez-Luna; Gunnar Sedin; Nim Subhedar
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

10.  Outcomes in neonates with pulmonary atresia and intact ventricular septum underwent pulmonary valvulotomy and valvuloplasty using a flexible 2-French radiofrequency catheter.

Authors:  Meng-Luen Lee; Lon-Yen Tsao; Han-Yao Chiu; Ming Chen; Ing-Sh Chiu
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.